drugset
drugset / Trial / NCT06618391

Local Injection and Systemic Therapy in the Treatment of NSCLC.

NCT06618391 ↗

Phase 2 Not yet recruiting 84 enrolled Henan Cancer Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective, exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection combined with systemic therapy in patients with locally advanced or advanced non-small cell lung cancer(NSCLC).

Timeline

Start
2024-10-08
Primary completion
2026-03-02
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Envafolimab Monoclonal antibody 150 mg Intrathecal
Subject Envafolimab Monoclonal antibody 300 mg Intrathecal
Subject Recombinant Human Adenovirus Type 5 Unknown 1 ml Intrathecal
Subject recombinant human endostatin Protein / enzyme biologic 15 mg Intravenous
Subject recombinant human endostatin Protein / enzyme biologic 210 mg Intravenous
Background Docetaxel Small molecule 60 mg/m2 Intravenous
Background Docetaxel Small molecule 75 mg/m2 Intravenous

Indications

non-small cell lung carcinoma